MYUNGMOON Pharm co.,Ltd (KRX:017180)

Market Cap	59.40B -7.4%
Revenue (ttm)	193.64B +7.5%
Net Income	1.46B
EPS	43.22
Shares Out	33.43M
PE Ratio	41.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,158
Average Volume	218,661
Open	1,731.00
Previous Close	1,731.00
Day's Range	1,713.00 - 1,850.00
52-Week Range	1,412.00 - 2,055.00
Beta	0.45
RSI	40.47
Earnings Date	Mar 18, 2026

About MYUNGMOON Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1983
• Employees: 291
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 017180

Financial Performance

In 2024, MYUNGMOON Pharm co.,Ltd's revenue was 186.44 billion, an increase of 9.95% compared to the previous year's 169.57 billion. Losses were -3.03 billion, -32.94% less than in 2023.